Abby Reinhard, Assistant Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2021. Email her at firstname.lastname@example.org
1-Week Epworth Sleepiness Scale for Children and Adolescents Validated for Pediatric Narcolepsy
The study is the first to support the validity of the ESS-CHAD in pediatric participants under the age of 12 years, showing internal consistency, test-retest reliability, responsiveness to change, and construct validity.
Bright Ambient Light Improves Sleep Disturbances in Older Adults With Dementia
The light intervention was found to reduce awakening time at night, delay sleep offset, and advance sleep onset in a small patient population with dementia.
Diverse Enrollment, Primary End Point Announced for Phase 4 ENVISION Study of Aducanumab
Eighteen percent of the Alzheimer disease treatment’s study participants are anticipated to be Black/African American and Latinx, according to an announcement from Biogen and Eisai.
Third mRNA COVID-19 Vaccine Dose Safe for Patients With Multiple Sclerosis
Results from the cohort study suggest that a third dose was also associated with modestly increased levels of anti-SARS-CoV02 spike receptor-binding immunoglobulin G antibodies in those who had reduced protective humoral immunity before reimmunization.
Risdiplam Gets Priority Review for Presymptomatic SMA in Babies Under 2 Months
The submission to the FDA is supported by interim data from the RAINBOWFISH trial (NCT03779334), as all 5 babies treated with risdiplam maintained the ability to swallow and feed exclusively orally after 12 months.
Actigraphy Identified as a Valid Tool for Sleep Assessment in Children With Cerebral Palsy
Investigators developed a weighted logistic regression-based sleep-wake scoring method for actigraphy data, concluding that it aided in assessing sleep in CP.
Application Accepted for Oral Edaravone in Amyotrophic Lateral Sclerosis
The FDA accepted the new drug application for priority review, setting a PDUFA action date of May 12, 2022.
FDA Places Clinical Hold on IND for DNL919 in Alzheimer Disease
The clinical hold comes 2 days after an announcement from Denali Therapeutics detailing a partnership with Takeda Pharmaceutical Company to codevelop and cocommercialize the treatment.
Patients With COVID-19-Related Disorders of Consciousness May Invariably Recover Consciousness
Dubbed COVID-DoC, the prospective study is the largest of its kind to date and provides initial data on the prognosis and pathophysiology of the condition in a group of patients at Massachusetts General Hospital.
Neurodegenerative Biomarkers Elevated in Hospitalized Patients With COVID-19
The study of 251 hospitalized patients with COVID-19 found that biomarkers were elevated to levels that were similar to—or even higher than—those observed in patients with Alzheimer disease.
Partial Clinical Hold Placed on Multidose Clinical Trials of YTX-7739 in Parkinson Disease
Yumanity Therapeutics announced the hold, which was in response to an investigational new drug application submitted to the FDA in December 2021.
First Patient Enrolled in ENSURE-2 Trial of IMU-838 for Relapsing Multiple Sclerosis
The trial is a twin of ENSURE-1, which began in November 2021, and is supported by positive clinical data from the phase 2 EMPhASIS trial.
Compassionate Use Clinical Trial of FGF-1 Initiated for Amyotrophic Lateral Sclerosis
Zhittya Genesis Medicine announced the trial to evaluate its biological drug, FGF-1, which is administered via an intranasal delivery device, in a cohort of individuals with mild to moderate ALS.
Women Show Lower Risk of Early Stroke Deaths, Poststroke Infections
Investigators suggest that sex-specific strategies should be invoked to reduce the amount of early stroke deaths after observations suggest that female sex is linked to lower risk of stroke-related events.
Understanding Disorders of Consciousness Associated With Severe COVID-19
David Fischer, MD, neurocritical care fellow at Massachusetts General Hospital and Brigham and Women’s Hospital, outlined findings from a recent study that evaluated hospitalized patients with COVID-19 who were not regaining consciousness.
Plasma Tau Levels Serve as Biomarkers of Cognitive Decline in Lewy Body Dementia
Investigators measured p-tau181 and p-tau231 levels with in-house single molecule array assays and cognition with the Mini-Mental State Examination.
Essential Tremor Heritability Explained by Common Genetic Variation
The results, which included data from more than 7000 patients with ET and almost 500,000 individuals overall, may help identify new common genetic risk factors for ET.
Evaluating Neurodegenerative Biomarkers in Hospitalized Patients With COVID-19, Alzheimer Disease
Jennifer Frontera, MD, professor of neurology, NYU Langone Grossman School of Medicine, discussed findings from a recently published study investigating neurological complications in hospitalized patients with COVID-19.
Long-Term IV Edaravone Not Associated With Disease-Modifying Benefit in ALS
Despite not providing additional, clinically relevant benefit for patients with amyotrophic lateral sclerosis as an add-on to standard therapy, the intravenous treatment was feasible and well tolerated.
ANAVEX 3-71 Meets Primary, Secondary End Points in Phase 1 Study
The Anavex Life Sciences treatment was found to be well tolerated in all cohorts of healthy patients with no serious adverse events reported. It is in development for conditions such as frontotemporal dementia.
Comprehensive Care and Collaboration for Multiple Sclerosis
Reflecting on 2021, Mitzi Joi Williams, MD, the founder and CEO of Joi Wellness Group MS Center discussed the positive repercussions of the COVID-19 pandemic, which allowed for more freedom when sharing data.
Telemedicine’s Effect on Symptom Management, Care for Minority Populations in MS
Mitzi Joi Williams, MD, founder and CEO of Joi Wellness Group Multiple Sclerosis Center, shared her thoughts on changes to the MS care model over the past year, as well as how the pandemic and telehealth have affected care for underrepresented populations.
Long-term Functional Outcomes Improved in Ischemic Stroke But Not Hemorrhagic
Investigators partly attribute different trends in ischemic vs hemorrhagic strokes to differences in the development of acute therapeutic strategies over the 20-year study period.
Long-term Mortality Increased After Pediatric Ischemic Stroke
Mortality remained elevated even after 20 years poststroke, highlighting the importance of long-term follow-up in this patient population.
The SAGE Test: Study Findings, Applications, and Future Potential
Douglas Scharre, MD, discussed the key findings from a recent study evaluating the Self-Administered Gerocognitive Exam and its application for at-risk populations.
EAT-Lancet Diet, AHEI Associated With Lower Risk of Stroke, Subtypes of Stroke
According to the study, which assessed the EAT-Lancet diet and Alternate Health Eating Index-2010 in more than 2000 patients, dietary pattern has a distinct association with different stroke subtypes.
Discussing Advantages, Potential of the SAGE Test for Early Dementia Detection
Douglas Scharre, MD, provided an overview of the pen-and-paper and digital versions of the test, which do not require an administrator.
OSA Severity Measures Independently Associated With Spindle Abnormalities in Men
The authors noted that future studies should investigate this association to identify patients with obstructive sleep apnea who are at risk of potential cognitive decline and adverse health function.
Proportion of Pregnant Women With Epilepsy Using Valproate Declined, German Study Finds
Investigators assert there is still room for improvement to further minimize exposure, as the treatment was used in a relevant number of pregnancies in 2016.
SAGE Test Detects Early Dementia At Least 6 Months Sooner Than MMSE
Investigators also pointed to the potential repetitive administration of the SAGE test to identify stability or decline, effectively providing an objective cognitive biomarker.
2 Commerce Drive Cranbury, NJ 08512